Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (435)	12/4/1997 8:51:00 PM
From: Bruce Russell	Read Replies (3) \| Respond to of 1580

The MK869 is very big news. It gives the prospect of back filling and overcoming the patent expirations of Vasotec, Pepcid and Mevacor in 1999, 2000 and 2001 (about 3 billion in revenues). If MK-869 does what Prozac and Buspar do without the cotten mouth, it will be a super block buster, and should hit market in 2001. Merck's already going to do well with Propesia, Singulaire, Maxalt, Cox-2, all of them could be Billion sellers, who knows how well Propecia will sell, if all the young balding computer nerds buy it. Regards, Bruce